CD8A and glioblastoma: Furthermore, early ImmunoPET evaluation of CD8+ cell populations in GBM have demonstrated the ability of this approach to monitor CD8+ cell infiltration following immunotherapy in preclinical immunocompetent 31 and humanized models 32.